The therapeutic effects of anti-CTLA4 antibodies in mice with melanoma were also observed in experiments in which data from colitis and tumor models were compared to mice receiving anti-CTLA4 antibodies similar to ipilimumab patients, consistent with clinical observations. Here, CTLA4 is linked to melanoma.